



Please find our Research on Bloomberg BRYG <GO>

23rd June 2016

BG's Wake Up Call

	Last close	Daily chg (%)	Chg YTD (%)
Indices			
Dow Jones	17780.83	-0.27%	+2.04%
S&P 500	2085.45	-0.17%	+2.03%
Nasdaq	4833.32	-0.22%	-3.48%
Nikkei	16238.35	+1.07%	-15.59%
Stoxx 600	341.325	+0.38%	-6.69%
CAC 40	4380.03	+0.29%	-5.54%
Oil /Gold			
Crude WTI	48.38	-1.25%	+30.05%
Gold (once)	1266.97	-0.28%	+19.26%
Currencies/Rates			
EUR/USD	1.1282	+0.10%	+3.86%
EUR/CHF	1.08275	+0.24%	-0.43%
German 10 years	0.06	+25.70%	-90.52%
French 10 years	0.428	+0.25%	-56.42%
Euribor	-	+-%	+-%

Economic releases :

Date	
23rd-Jun	GB - Brexit Referendum
	DE - Markit Services PMI (55E)
	US - Initial Jobless claims (270K E)
	US - New Home Sales May (-9.5%)
	US - Leading indicators May (0.2% E)

Upcoming BG events :

Date	
27th-Jun	IMERYS (BG Luxembourg with CFO)
13th-Jul	Galapagos (BG Paris Roadshow with CFO)
14th-Nov/ 15th-Nov	4th Paris Healthcare Conference
28th-Nov/ 29th-Nov	2nd Paris Consumer Conference

Recent reports :

Date	
22nd-Jun	ELIOR On track with 2020 Ambitions
22nd-Jun	AXA Ready for the next run
22nd-Jun	INFINEON Underestimated potential
21st-Jun	GENMAB The saga goes on!
21st-Jun	GENMAB The saga goes on!
16th-Jun	UTILITIES Haste makes waste, it's upside time!

List of our Reco & Fair Value : Please click here to download



MONCLER

BUY, Fair Value EUR17 (+10%)

Moncler keeps up the momentum

Given Moncler's highly seasonal business (F/W collections: 75% of sales), Q2 is the smallest quarter of the year accounting for ~10% of FY revenues on average over the 2013-15 period. However, this does not prevent the group from delivering further robust momentum that clearly outpaces its luxury peers, and we anticipate 13% FX-n growth for Q2, vs. -1-0% on average for our luxury sample. Buy recommendation and FV of EUR17 confirmed.

TESCO

SELL, Fair Value 166p (+1%)

A first take on Q1 sales prompts no change to our view on the stock (sell)

UK LFL sales growth came in at 0.3% in Q1 vs +0.2% expected by the consensus (volumes and transactions up 2.2% and 1.7% respectively). International LFL sales growth worked out at 3.0% in Q1 vs +2.8% expected by the consensus (volumes and transactions up 2.7% and 1.5% respectively). On the whole, the statement was pretty much in line with expectations and at this stage, does not allow us to amend our mitigated view on the stock. Sell maintained.

BREMAIN or BREXIT

Bremain or Brexit: moment of truth

Luxury & Consumer Goods

Moncler

Price EUR15.43

Moncler keeps up the momentum

Fair Value EUR17 (+10%)

BUY

Bloomberg	MONC.IM
Reuters	MONC.MI
12-month High / Low (EUR)	18.9 / 12.2
Market Cap (EUR)	3,860
Ev (BG Estimates) (EUR)	3,815
Avg. 6m daily volume (000)	1,194
3y EPS CAGR	10.3%

	1 M	3 M	6 M	31/12/15
Absolute perf.	2.9%	6.4%	22.3%	19.4%
Pers & H/H Gds	2.1%	4.2%	4.7%	1.8%
DJ Stoxx 600	1.0%	0.3%	-4.4%	-6.7%

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	880.4	978.1	1,081	1,181
% change		11.1%	10.5%	9.2%
EBITDA	300	331	365	399
EBIT	252.7	282.6	311.8	340.9
% change		11.8%	10.4%	9.3%
Net income	163.8	185.2	205.8	226.3
% change		13.1%	11.1%	10.0%

	2015	2016e	2017e	2018e
Operating margin	28.7	28.9	28.8	28.9
Net margin	18.6	18.9	19.0	19.2
ROE	30.0	27.5	25.4	23.7
ROCE	40.9	42.8	45.2	47.8
Gearing	9.1	-6.7	-19.0	-28.9

(EUR)	2015	2016e	2017e	2018e
EPS	0.69	0.75	0.84	0.92
% change	-	10.0%	10.9%	9.8%
P/E	22.5x	20.5x	18.4x	16.8x
FCF yield (%)	3.4%	4.0%	4.6%	5.2%
Dividends (EUR)	0.14	0.17	0.21	0.23
Div yield (%)	0.9%	1.1%	1.3%	1.5%
EV/Sales	4.4x	3.9x	3.4x	3.0x
EV/EBITDA	13.0x	11.5x	10.1x	9.0x
EV/EBIT	15.5x	13.3x	11.7x	10.4x



Given Moncler's highly seasonal business (F/W collections: 75% of sales), Q2 is the smallest quarter of the year accounting for ~10% of FY revenues on average over the 2013-15 period. However, this does not prevent the group from delivering further robust momentum that clearly outpaces its luxury peers, and we anticipate 13% FX-n growth for Q2, vs. -1-0% on average for our luxury sample. Buy recommendation and FV of EUR17 confirmed.

ANALYSIS

- **A lack of tourists in Europe partly offset by local customers.** Like other luxury groups, Moncler has witnessed a decline in tourist flows in Italy, France and Belgium, mostly Asian travellers, following the terror attacks in Brussels and a less attractive price gap between Europe and Greater China. However, we understand that demand from the local clientele was good and that the group was not affected by unfavourable weather conditions.
- **Solid performances expected in Asia-Pacific...** In Q2, Moncler's key markets (**Greater China, South Korea**) should continue to drive the group's growth in Asia-Pacific, even in **Japan** (~15% of sales) where the Italian brand still enjoys the positive impact from the opening of the flagship store in Ginza last October (=> higher share of Chinese customers there). Moreover, Moncler's operations in **Greater China** may have benefited from a pick-up in domestic consumption since Chinese clients travelled less during the quarter.
- **... and in North America.** After a strong first quarter (+21% FX-n), the Italian group maintained robust growth in the region (+17%e). This performance was balanced between Retail and Wholesale, thanks to a selective approach with these wholesalers, its upscale positioning (no discounts) and a cautious replenishment management (low risks of excess inventory).

Moncler's organic growth by quarter (%):

FX-n growth	Q1 2015	Q2 2015	Q1 2016	Q2 2016e
Italy	7	11	5	2
EMEA excl. Italy	19	15	5	4
Asia & RoW	48	10	30	27
Americas	61	83	21	17
Total Revenues	30	20	17	13

Source: Company Data, BG ests

- **Limited decline in adj. EBITDA margin in H1 (-30bp to 23.7%).** This forecast is consistent with our FY assumption (-30bp to 33.8%). We expect a 10bp-improvement in the GM (to 72.8%) driven by the positive channel-mix while the integration of a second Romanian supplier (March 2016) might imply a slight dilutive impact. We anticipate a 60bp increase in opex (to 55.1%) given retail expansion (+3 stores in Q2) and start-up costs implied by the (soft) opening of the flagship store in London and the future new flagship store in NYC (Madison Ave. in Q3 2016).
- **Investment case confirmed so far.** We favour Moncler for its heritage and strong legitimacy that enables the brand to outperform the highly fragmented and dynamic outerwear segment (~+5%/year). The growth story is about top line (~10% CAGR during 2015-18), driven by the group's excellent control of the retail channel (~70% of 2015 sales). As a reminder, during the Q1 conference call CCO Luciano Santel was pleased by KPIs at the new stores, some of them even delivered results above expectations. Yet, Moncler is focusing on improving efficiency further (CRM, relocations and refurbishments).

VALUATION

- The stock has soared 19% ytd vs. -6% on average for our luxury sample. It now trades at 11.7x 2017e EV/EBIT vs. 11.5x for the peer group. Ahead of Brexit results, it is worth noting that the UK only accounts for 4-5% of Moncler's sales and the vast majority of its costs are denominated in EUR.

NEXT CATALYSTS

- Moncler will report its H1 2016 results on 27th. [Click here to download](#)



Analyst:
Cédric Rossi
33(0) 1 70 36 57 25
crossi@bryangarnier.com

Consumer Analyst Team:
Nikolaas Faes
Loïc Morvan
Antoine Parison
Virginie Roumage

Food retailing

Tesco

Price 164.15p

A first take on Q1 sales prompts no change to our view on the stock (sell)

Fair Value 166p (+1%)

SELL

Bloomberg	TSCO LN
Reuters	TSCO.L
12-month High / Low (p)	223.7 / 139.2
Market Cap (GBpm)	13,418
Ev (BG Estimates) (GBpm)	21,346
Avg. 6m daily volume (000)	29 356
3y EPS CAGR	103.4%

	1 M	3 M	6 M	31/12/15
Absolute perf.	-0.1%	-16.9%	13.0%	9.8%
Food Retailing	-0.7%	-3.5%	-0.2%	-1.3%
DJ Stoxx 600	0.6%	-0.2%	-4.8%	-7.0%

YEnd Feb. (GBpm)	02/16	02/17e	02/18e	02/19e
Sales	54,433	56,245	57,696	58,948
% change		3.3%	2.6%	2.2%
EBITDA	2,278	2,225	2,437	2,581
EBIT	1,046	1,069	1,252	1,370
% change		2.2%	17.1%	9.4%
Net income	103.5	473.0	606.7	866.2
% change		NM	28.3%	42.8%

	02/16	02/17e	02/18e	02/19e
Operating margin	1.7	1.9	2.2	2.3
Net margin	0.2	0.8	1.1	1.5
ROE	NM	NM	NM	NM
ROCE	4.5	5.2	6.1	6.8
Gearing	59.3	48.5	38.5	30.6

(p)	02/16	02/17e	02/18e	02/19e
EPS	1.27	5.83	7.48	10.68
% change	-	NM	28.3%	42.8%
P/E	NS	28.1x	21.9x	15.4x
FCF yield (%)	0.1%	0.1%	0.1%	0.1%
Dividends (p)	0.00	0.88	2.24	4.27
Div yield (%)	NM	0.5%	1.4%	2.6%
EV/Sales	0.4x	0.4x	0.4x	0.3x
EV/EBITDA	9.7x	9.6x	8.5x	6.1x
EV/EBIT	21.2x	20.0x	16.5x	11.5x

UK LFL sales growth came in at 0.3% in Q1 vs +0.2% expected by the consensus (volumes and transactions up 2.2% and 1.7% respectively). International LFL sales growth worked out at 3.0% in Q1 vs +2.8% expected by the consensus (volumes and transactions up 2.7% and 1.5% respectively). On the whole, the statement was pretty much in line with expectations and at this stage, does not allow us to amend our mitigated view on the stock. Sell maintained.


In the UK (~75% of revenues), Q1 2016/17 LFL sales growth excl. fuel and VAT (main kpi) came in at 0.3% (vs +0.9% in Q4 and -1.5% Q3 LY) vs +0.2%e. Beyond the figures, management indicates that new exclusive fresh food brands (deflationary impact of 0.7% on total UK LFL) are performing well in the UK.

In ROI (~4% of revenues), Q1 LFL sales growth excl. fuel and VAT worked out to 0.3% (vs +1.0% in Q4 and -1.2% Q3 LY) vs +0.7%e.

Overseas (~19% of revenues), sales momentum remained healthy with a 3.0% LFL rate (+3.8% in Q4 and +2.7% in Q3 LY) vs +2.8%e.

In detail concerning international activities, LFL sales growth worked out to 3.3% in Asia (~8% of revenues) vs +2.8%e and +2.8% in Europe (~11% of revenues) vs +2.9%e.

Market share in the UK (Kantar / 12 weeks moving average)



Source: Kanrat worldapanel

ANALYSIS & REMINDER OF OUR INVESTMENT CASE

- An improvement in the major balances (ND/EBITDA ratio of ~5.0x) depends on a recovery in lfl growth in the UK (+0.2% LFL currently vs ~2% needed, *ceteris paribus*, to cover natural cost inflation). There is still a long way to go in an environment that remains disrupted by discounters.
- Given the sluggishness specific to the sector, Tesco's commercial resolutions could take time to produce their effects. Growth is at a standstill (a disruptive factor in a fixed-cost industry, as Tesco's CEO Dave Lewis hinted at when he spoke of a "lethal cocktail of costs" in the UK).
- Note that the CEO stated that it would be "a significant, significant achievement" to meet analysts' estimates for operating profit of GBP1.25bn this year. So in the end, even if we do not question the ongoing commercial recovery, we are sticking to our cautious stance.

VALUATION

- NM

NEXT CATALYSTS

- Significant improvement in LFL sales growth in the UK & in ROI (i.e. > 2%)



Analyst :
Antoine Parison
33(0) 1 70 36 57 03
aparison@bryangarnier.com

Sector Team :
Nikolaas Faes
Loïc Morvan
Cédric Rossi
Virginie Roumage

Main View

Bremain or Brexit: moment of truth



- A Brexit would open the door for tons of negotiations, implying increased uncertainty and risk. However, we prefer not to speculate on the potential mid-term business implications as these would mainly depend on the future rules the UK would be able to negotiate with its "partners".
- At this stage, we are focusing only on the relative sensitivities to FX issues for stocks we cover. Our FX assumptions are: GBP down vs. main currencies, CHF and USD up vs. main currencies inc. EUR.
- Below we highlight the companies we cover that show some degree of sensitivity to this issue from a P&L standpoint, depending on their currency-mix and the currency they report in.

[Click here to download](#)

Company type	Reporting in	Impact on P&L in case of Brexit	Names
UK companies	GBP	+ (business outside of the UK will translate into more GBP)	ARM, Burberry, Compass, Diageo, GSK, Sage, Tesco, Worldpay
	USD	- (business in EUR/GBP will translate into less USD)	Astra, Intercontinental, Shire
UK "pure domestic"	GBP	= (no FX issue)	Pennon

Non-UK companies	EUR	- (business in GBP will translate into less EUR)	Accor, Atos, Carlsberg, Heineken, Sopra, Sword, Unilever
------------------	-----	--	--

FX event	Accounts in	Impact on P&L in case of Brexit	Names
CHF up	CHF	- (business out of Switzerland will translate into less CHF)	Actelion, LafargeHolcim, Nestlé, Roche, SGS, Swatch
	EUR	- (in case of high portion of costs in CHF)	Richemont (but less negative than Swatch)
USD up	EUR	+ (business in USD will translate into more EUR)	Ahold/Delhaize, Altice, Axway, BIC, Bureau Veritas, Capgemini, Cast, CRH, Dassault Systèmes, Essilor, Fresenius Med. Care, Heidelberg, Heineken, Infineon, Luxottica, LVMH, Melia, Pernod, Rémy Cointreau, Sanofi, SAP, Sodexo, Software AG, Soitec, St Gobain
	EUR	- (due to a high portion of costs in USD)	Adidas, SEB
	USD	- (business in EUR/GBP will translate into less USD)	AB Inbev, Temenos
	USD	+ (thanks to a high portion of costs in EUR)	Dialog, STM

Specific comments on Financials

Potential end of the "European passport" A major legal/operating/financial issue for banks with significant CIB activities located in the UK: US bulge brackets, HSBC (reporting in USD), Deutsche Bank + BNPP/SG to a lesser extent.
Also a major issue for UK located insurers with major activities outside of the UK (Prudential, Aviva, Lloyd's affiliates...).

Concerning companies we cover Basically the prospect is negative for all insurers as Brexit would favour a flight to quality -> bad news for investment returns and solvency II margins.
AXA, Allianz and Aegon have limited UK activities (5-6% of operating profit).
Allianz would benefit from higher a USD and lower US rates thanks to Pimco's business.
Aegon and AXA would benefit from a higher USD but would suffer from lower US rates.
Zurich is a little more exposed to the UK (8%) and would suffer from a higher USD (accounts are in USD).
Reinsurers are usually seen as safe havens within the financial sector and would benefit from a higher USD (excluding Swiss Re which reports in USD), but bear in mind that reinsurers have a higher UK exposure (15%) compared to primary insurers.



Analyst:
Olivier Pauchaut
33(0) 1 56 68 75 49
opauchaut@bryangarnier.com

BG's Wake Up Call

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 56.5%

NEUTRAL ratings 34%

SELL ratings 9.5%

Bryan Garnier Research Team

Healthcare Team	Pharmaceuticals	Eric Le Berrigaud <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Biotech/Medtech	Mickael Chane-Du	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
	Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Consumer Team	Luxury/Consumer Goods	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	Beverages	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retailing	Antoine Parison	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
	Luxury /Consumer Goods	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
TMT	Video Games / Payments	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Semiconductor	Dorian Terral	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
Utilities		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
		Pierre-Antoine Chazal	33 (0) 1 56 68 75 06	pachazal@bryangarnier.com
Insurance		Olivier Pauchaut <i>(Head of Research)</i>	33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Hotels/Business Services		Bruno de La Rochebrochard	33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
Construction/ Infrastructures Building Materials		Eric Lemarié	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Marketing		Sophie Braincourt	33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
Market Data & Information Systems Manager		Eric Monnier	33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Munich	New Delhi
Beaufort House 15 St. Botolph Street London EC3A 7BB Tel: +44 (0) 207 332 2500 Fax: +44 (0) 207 332 2559	26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01 Regulated by the Financial Conduct Authority (FCA) and the Autorité de Contrôle prudentiel et de résolution (ACPR)	750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member	Widenmayerstrasse 29 80538 Munich Germany +49 89 2422 62 11	The Imperial Hotel Janpath New Delhi 110 001 Tel +91 11 4132 6062 +91 98 1111 5119 Fax +91 11 2621 9062 Geneva rue de Grenus 7 CP 2113 Geneve 1, CH 1211 Tel +4122 731 3263 Fax+4122731 3243 Regulated by the FINMA



BRYAN, GARNIER & Co

Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB , United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris , France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research.

These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....